Resverlogix to Present at Upcoming Conferences
13 October 2021 - 11:00PM
Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a
world leader in epigenetics or gene regulation, announces today
that President and CEO Donald McCaffrey will be presenting
virtually at the following conferences:
14th Annual LD Micro
Main Event Conference
Resverlogix will give a virtual presentation at the LD Micro
Main Event Conference on October 14th. Mr. McCaffrey will deliver
his corporate presentation at 9:30 AM ET. Register to watch the
presentation HERE.
Benzinga ALL ACCESS International
Resverlogix will also be participating in the Benzinga ALL
ACCESS virtual event on October 22nd. Mr. McCaffrey’s
presentation and interview will take place at 1:30 pm ET. Register
to watch the live event HERE.
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, epigenetic small
molecule, or gene regulating, therapeutic candidate. It is a
selective BET (bromodomain and
extra-terminal) inhibitor, which
works in preventing disease by turning genes on and/or off through
regulation of gene expression. The prevalence of BET proteins
in the human body allows apabetalone, through its unique
mechanism of action, to simultaneously target multiple
disease-causing biological processes while maintaining a well
described safety profile – leading to a new way to treat chronic
disease.
Cardiology:
In February 2020, apabetalone became the first therapy of its
kind to receive Breakthrough Therapy Designation by the US Food and
Drug Administration (FDA) – for a major cardiovascular indication –
following the groundbreaking findings from the BETonMACE Phase
Three study. Data from BETonMACE showed apabetalone can potentially
prevent major adverse cardiac events among high-risk cardiovascular
disease patients who also have type 2 diabetes mellitus.
Covid-19:
On March 23, 2020, Resverlogix launched its
COVID-19 program, enlisting world-renowned collaborators. Studies
demonstrate that apabetalone has the potential to act against
COVID-19 with a unique dual-mechanism: the first pillar of
apabetalone’s dual-mechanism is preventing viruses from entering
the cells and replicating; the second pillar is averting runaway
inflammatory reactions that can cause severe and lasting organ
damage. A Phase Two clinical trial is evaluating apabetalone in
combination with standard of care for patients hospitalized with
COVID-19. Apabetalone treatment could potentially reduce the
severity and duration of COVID-19. Apabetalone’s unique
dual-mechanism also means that it is likely to show efficacy
against COVID-19 variants and may even help fight other related
viruses.
Apabelalone is the only drug of its class with a
well-established safety record in human clinical trials, with well
over 4200 patient-years on drug across 10 clinical trials.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage
biotechnology company and the world leader in epigenetics, or gene
regulation, with the goal of developing first-in-class therapies
for the benefit of patients with chronic disease.
Resverlogix is commercializing a new class of epigenetic
therapies designed to regulate gene expression, turning
disease-associated genes “on” or “off”. We aim to improve patients’
lives by restoring biological functions – altered by serious
illnesses such as cardiovascular disease – back to a healthier
state.
The Company’s clinical program is focused on evaluating the lead
epigenetic candidate apabetalone for the treatment of
cardiovascular disease and associated comorbidities, and
COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us: Twitter: @Resverlogix_RVX. LinkedIn:
https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain
forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward
looking information related to the potential role of Apabetalone in
the treatment of patients with COVID-19 (and potentially other
viruses), cardiovascular disease and associated comorbidities and
other chronic diseases. Our actual results, events or developments
could be materially different from those expressed or implied by
these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our
Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information please contact:
Investor RelationsEmail:
ir@resverlogix.comPhone:
403-254-9252www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Resverlogix (TSX:RVX)
Historical Stock Chart
From Jan 2024 to Jan 2025